Prostatype Genomics
4.32
SEK
-7.3 %
Less than 1K followers
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
-7.3%
-47.32%
-61.08%
-48.26%
-81.22%
-84.25%
-98.53%
-
-99.36%
Prostatype Genomics is active in medical technology. The company specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. The operations are found worldwide with the largest presence in the Nordic market.
Read moreMarket cap
29.53M SEK
Turnover
65.72K SEK
Revenue
200K
EBIT %
-20,425 %
P/E
-
Dividend yield-%
-
Financial calendar
22.5
2025
General meeting '25
23.7
2025
Interim report Q2'25
12.2
2026
Annual report '25
ShowingAll content types
Prostatype Genomics submits supplementary answers in the final phase of its Medicare application for reimbursement in the United States
Health economics study published – Prostatype® can provide 800 MSEK in annual health economic benefit in Sweden according to complementary analysis
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools